|
Quality of Life in Children Treated for Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Quality of Life in Children Treated for Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Quality of Life in Children Treated for Cancer Clinical research trials and Quality of Life in Children Treated for Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Quality of Life in Children Treated for Cancer. Quality of Life in Children Treated for Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Quality of Life in Children Treated for Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Quality of Life in Children Treated for Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "Q" Clinical Trials Conditions > Quality of Life in Children Treated for Cancer  Quality of Life in Children Treated for Cancer
Quality of Life in Children Treated for Cancer
For Condition: Lymphoma,Leukemia
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Children's Cancer Group
Synopsis: RATIONALE: Questionnaires that measure quality of life may improve the ability to plan treatment for children with cancer. PURPOSE: Randomized clinical trial to study quality of life in children treated for cancer.
Details: OBJECTIVES: I. Assess the validity and reliability of a quality of life questionnaire (MM-QOL) that is being developed for patients with previously or currently treated childhood cancers. PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (8-12 vs 13-20) and treatment (current vs previous). Patients are randomized to one of two arms of the study. Arm I (Reliability): Patients will complete the same questionnaire two weeks apart. (age 13-20 stratum closed as of 7/14/00) Arm II (Validity): Patients will complete a study questionnaire plus a Child Health Questionnaire. Patients between ages 8-12 are interviewed and patients between ages 13-20 complete a written questionnaire. PROJECTED ACCRUAL: A total of 716 patients (416 for arm I (208 for 8-12 age group and 208 for 13-20 age group) and 300 for arm II (150 for 8-12 age group and 150 for 13-20 age group)) will be accrued for this study.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 8 Years/20 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Prior or current diagnosis of any pediatric cancer; Current chemoradiotherapy (at least 2 months since start of therapy) OR At least 1 year since prior treatment and in remission --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: See Disease Characteristics - Endocrine therapy: Not specified - Radiotherapy: See Disease Characteristics - Surgery: Not specified --Patient Characteristics-- - Age: 8 to 20 - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
SmitaBhatia, Study Chair, Children's Cancer Group
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
United States
CCOP - Christiana Care Health Services
Wilmington, Delaware, 19899
United States
CCOP - Duluth
Duluth, Minnesota, 55805
United States
CCOP - Geisinger Clinic and Medical Center
Danville, Pennsylvania, 17822-2001
United States
Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, 91010-3000
United States
CCOP - Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503
United States
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309-1016
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
United States
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, 57104
United States
CCOP - Marshfield Medical Research and Education Foundation
Marshfield, Wisconsin, 54449
United States
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
United States
CCOP - Colorado Cancer Research Program, Inc.
Denver, Colorado, 80209-5031
United States
Children's Hospitals and Clinics - Minneapolis
Minneapolis, Minnesota, 55404
United States
CCOP - Merit Care Hospital
Fargo, North Dakota, 58122
United States
Children's Hospitals and Clinics of Minnesota
St. Paul, Minnesota, 55102
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000067920; NCI-P00-0148,CCG-AS972,CCG-S9702
Study Start Date: April 2000
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005881
Other Leukemia Studies:
1. Pharmacokinetic study of palifermin in subjects receiving radiation therapy and chemotherapy followed by blood stem cell support
2. Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
3. Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
4. Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
5. PS-341 in Treating Patients With Advanced Cancer
Related Studies:
Other Leukemia Clinical Trials
Other North Dakota Clinical Trials
Other Fargo Clinical Trials
Quality of Life in Children Treated for Cancer
|
|
|
|
|
|
|
|
